S1 Ep3: The Gene-Editing Company That Didn't Need CRISPR
Apr 13, 2018•26 min•Season 1Ep. 3
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
CRISPR, TALEN, and gene editing sound like the stuff of the future, but they are already changing medicine. What about zinc finger nucleases? That's what Sangamo Therapeutics uses to perform gene editing, and the tech recently earned the company a $3 billion deal. Today on Data Book, the origins of CRISPR and the Sangamo story.
For the best experience, listen in Metacast app for iOS or Android